Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Laws, Simon M ^a,b,c   Gaskin, Scott ^b   Woodfield, Amy ^b   Srikanth, Velandai ^d   Bruce, David ^e   Fraser, Paul E ^f,g   Porter, Tenielle ^a   Newsholme, Philip ^b   Wijesekara, Nadeeja ^f   Burnham, Samantha ^a,h   Doré, Vincent ^h,i   Li, Qiao Xin ^j   Maruff, Paul ^j,k   Masters, Colin L ^j   Rainey Smith, Stephanie ^a   Rowe, Christopher C ^i,j   Salvado, Olivier ^h   Villemagne, Victor L ^i,j   Martins, Ralph N ^a,l   Verdile, Giuseppe ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c Academic Centre for Community Mental Health   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h CSIRO   (Australia)

ⁱ AUSTIN HEALTH   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k Scientific Division   (Australia)

^l MACQUARIE UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; FEMALE; GENETICS; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; BIOMARKERS; COGNITION; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; TAU PROTEINS;

EID: 85028450581     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09577-4     Document Type: Article

References (83)

1. Leibson, C. L. et al. The risk of dementia among persons with diabetes mellitus: A population-based cohort study. Ann NY Acad Sci 826, 422-427 (1997).
2. Arvanitakis, Z. et al. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology 63, 996-1001 (2004).
3. Ott, A. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942 (1999).
4. Peila, R., Rodriguez, B. L., Launer, L. J. , Honolulu-Asia Aging, S. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262 (2002).
5. Xu, W. L., Qiu, C. X., Wahlin, A., Winblad, B. , Fratiglioni, L. Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology 63, 1181-1186 (2004).
6. Manschot, S. M. et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55, 1106-1113 (2006).
7. van Harten, B., Oosterman, J. M., Potter van Loon, B. J., Scheltens, P. , Weinstein, H. C. Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol 57, 70-74, doi:10.1159/000098054 (2007).
8. Moran, C. et al. Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care 36, 4036-4042, doi:10.2337/dc13-0143 (2013).
9. Biessels, G. J. , Reijmer, Y. D. Brain changes underlying cognitive dysfunction in diabetes: What can we learn from MRI Diabetes 63, 2244-2252, doi:10.2337/db14-0348 (2014).
10. Moran, C. et al. Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes 64, 279-283, doi:10.2337/db14-0506 (2015).
11. Kooistra, M. et al. Diabetes mellitus and progression of vascular brain lesions and brain atrophy in patients with symptomatic atherosclerotic disease. The SMART-MR study. J Neurol Sci 332, 69-74, doi:10.1016/j.jns.2013.06.019 (2013).
12. van Elderen, S. G. et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: A 3-year follow-up. Neurology 75, 997-1002, doi:10.1212/WNL.0b013e3181f25f06 (2010).
13. Verdile, G., Fuller, S. J. , Martins, R. N. The role of type 2 diabetes in neurodegeneration. Neurobiol Dis 84, 22-38, doi:10.1016/j. nbd.2015.04.008 (2015).
14. Verdile, G. et al. Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. Mediators Inflamm 2015, 105828, doi:10.1155/2015/105828 (2015).
15. Cohen, A. D. , Klunk, W. E. Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72 Pt A, 117-122, doi:10.1016/j.nbd.2014.05.001 (2014).
16. Roberts, R. O. et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med 55, 759-764, doi:10.2967/jnumed.113.132647 (2014).
17. Thambisetty, M. et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 70, 1167-1172, doi:10.1001/jamaneurol.2013.284 (2013).
18. Willette, A. A. et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11, 504-510, e501, doi:10.1016/j.jalz.2014.03.011 (2015).
19. Huxley, R., Barzi, F. , Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Metaanalysis of 37 prospective cohort studies. BMJ 332, 73-78, doi:10.1136/bmj.38678.389583.7C (2006).
20. Chatterjee, S. et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care 39, 300-307, doi:10.2337/dc15-1588 (2016).
21. Peters, S. A., Huxley, R. R. , Woodward, M. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383, 1973-1980, doi:10.1016/S0140-6736(14)60040-4 (2014).
22. Keane, K. N., Cruzat, V. F., Carlessi, R., de Bittencourt, P. I. Jr. , Newsholme, P. Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and beta-Cell Dysfunction. Oxid Med Cell Longev 2015, 181643, doi:10.1155/2015/181643 (2015).
23. Vandal, M. et al. Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes 63, 4291-4301, doi:10.2337/db14-0375 (2014).
24. Park, S., Kim, D. S., Kang, S. , Moon, N. R. beta-Amyloid-induced cognitive dysfunction impairs glucose homeostasis by increasing insulin resistance and decreasing beta-cell mass in non-diabetic and diabetic rats. Metabolism 62, 1749-1760, doi:10.1016/j. metabol.2013.08.007 (2013).
25. Miklossy, J. et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31, 1503-1515, doi:10.1016/j.neurobiolaging.2008.08.019 (2010).
26. Craft, S. et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17, 123-130 (1996).
27. Craft, S. et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168 (1998).
28. Reger, M. A. et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331 (2008).
29. Morris, J. K., Vidoni, E. D., Honea, R. A. , Burns, J. M. , Alzheimer's Disease Neuroimaging, I. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 35, 585-589, doi:10.1016/j.neurobiolaging.2013.09.033 (2014).
30. Pucci, G. et al. Sex-A nd gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res 120, 34-42, doi:10.1016/j.phrs.2017.03.008 (2017).
31. Unwin, N., Shaw, J., Zimmet, P. , Alberti, K. G. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 19, 708-723 (2002).
32. Janssen, I., Powell, L. H., Crawford, S., Lasley, B. , Sutton-Tyrrell, K. Menopause and the metabolic syndrome: The Study of Women's Health Across the Nation. Arch Intern Med 168, 1568-1575, doi:10.1001/archinte.168.14.1568 (2008).
33. Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H. , Smith, S. R. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 32, 949-958, doi:10.1038/ijo.2008.25 (2008).
34. Pike, C. J. Sex and the development of Alzheimer's disease. J Neurosci Res 95, 671-680, doi:10.1002/jnr.23827 (2017).
35. Benedict, C. et al. Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care 35, 488-494, doi:10.2337/dc11-2075 (2012).
36. Ekblad, L. L. et al. Insulin resistance is associated with poorer verbal fluency performance in women. Diabetologia 58, 2545-2553, doi:10.1007/s00125-015-3715-4 (2015).
37. Schuur, M. et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol 25, 561-568, doi:10.1007/s10654-010-9476-y (2010).
38. Elias, M. F. et al. The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol 57, 808-813 (2000).
39. Grober, E. et al. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14, 266-278, doi:10.1017/S1355617708080302 (2008).
40. Derby, C. A. et al. Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests. Neurology 80, 1307-1314, doi:10.1212/WNL.0b013e31828ab2c9 (2013).
41. Palta, P., Schneider, A. L., Biessels, G. J., Touradji, P. , Hill-Briggs, F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: A meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 20, 278-291, doi:10.1017/S1355617713001483 (2014).
42. Vincent, C. , Hall, P. A. Executive Function in Adults With Type 2 Diabetes: A Meta-Analytic Review. Psychosom Med 77, 631-642, doi:10.1097/PSY.0000000000000103 (2015).
43. Mehla, J., Chauhan, B. C. , Chauhan, N. B. Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J Alzheimers Dis 39, 145-162, doi:10.3233/JAD-131238 (2014).
44. Knight, E. M., Martins, I. V., Gumusgoz, S., Allan, S. M. , Lawrence, C. B. High-fat diet-induced memory impairment in tripletransgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging 35, 1821-1832, doi:10.1016/j.neurobiolaging.2014.02.010 (2014).
45. Takeda, S. et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107, 7036-7041, doi:10.1073/pnas.1000645107 (2010).
46. Wang, Y. et al. Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease. J Alzheimers Dis 43, 451-463, doi:10.3233/JAD-140972 (2015).
47. Ho, L. et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904, doi:10.1096/fj.03-0978fje (2004).
48. Hoscheidt, S. M. et al. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. J Alzheimers Dis 52, 1373-1383, doi:10.3233/JAD-160110 (2016).
49. Hoscheidt, S. M. et al. Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. J Cereb Blood Flow Metab. doi:10.1177/0271678X16663214 (2016).
50. Reiman, E. M. et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106, 6820-6825, doi:10.1073/pnas.0900345106 (2009).
51. Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3, 89ra57, doi:10.1126/scitranslmed.3002156 (2011).
52. Bales, K. R. et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29, 6771-6779, doi:10.1523/JNEUROSCI.0887-09.2009 (2009).
53. Morris, J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131, doi:10.1002/ana.21843 (2010).
54. Lim, Y. Y. et al. Abeta amyloid, cognition, and APOE genotype in healthy older adults. Alzheimer's & dementia: The journal of the Alzheimer's Association 9, 538-545, doi:10.1016/j.jalz.2012.07.004 (2013).
55. Lim, Y. Y. et al. APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36, 1239-1244, doi:10.1016/j.neurobiolaging.2014.12.008 (2015).
56. LaDu, M. J. et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 269, 23403-23406 (1994).
57. Yang, D. S. et al. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoformspecific manner. Neuroscience 90, 1217-1226 (1999).
58. Hone, E. et al. Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7, 303-314 (2005).
59. Deane, R. et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013, doi:10.1172/JCI36663 (2008).
60. Sharman, M. J. et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 21, 403-409, doi:10.3233/JAD-2010-100141 (2010).
61. Irizarry, M. C. et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 90, 1132-1143, doi:10.1111/j.1471-4159.2004.02581.x (2004).
62. Hass, S., Weidemann, A., Utermann, G. , Baier, G. Intracellular apolipoprotein E affects Amyloid Precursor Protein processing and amyloid Abeta production in COS-1 cells. Mol Genet Genomics 265, 791-800 (2001).
63. Ishii, M. , Iadecola, C. Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. Cell Metab 22, 761-776, doi:10.1016/j.cmet.2015.08.016 (2015).
64. Bharadwaj, P. et al. The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-beta, Amylin, and Tau Proteins. J Alzheimers Dis, doi:10.3233/JAD-161192 (2017).
65. Nestor, P. J., Fryer, T. D., Smielewski, P. , Hodges, J. R. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54, 343-351, doi:10.1002/ana.10669 (2003).
66. Cross, D. J. et al. Loss of olfactory tract integrity affects cortical metabolism in the brain and olfactory regions in aging and mild cognitive impairment. J Nucl Med 54, 1278-1284, doi:10.2967/jnumed.112.116558 (2013).
67. Macesic, M. et al. Impaired Insulin Sensitivity And Secretion In Patients With Alzheimer's Disease: The Relationship With Other Atherosclerosis Risk Factors. Curr Vasc Pharmacol (2016).
68. Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687, doi:10.1017/S1041610209009405 (2009).
69. Burnham, S. C. et al. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. J Alzheimers Dis 46, 1079-1089, doi:10.3233/JAD-143015 (2015).
70. Wallace, T. M., Levy, J. C. , Matthews, D. R. Use and abuse of HOMA modeling. Diabetes Care 27, 1487-1495 (2004).
71. Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
72. Levy, J. C., Matthews, D. R. , Hermans, M. P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21, 2191-2192 (1998).
73. Brown, B. M. et al. Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology 83, 1345-1352, doi:10.1212/WNL.0000000000000867 (2014).
74. Li, Q. X. et al. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-beta Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimers Dis 48, 175-187, doi:10.3233/JAD-150247 (2015).
75. Vanderstichele, H. et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73, doi:10.1016/j.jalz.2011.07.004 (2012).
76. Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283, doi:10.1016/j.neurobiolaging.2010.04.007 (2010).
77. Clark, C. M. et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283, doi:10.1001/jama.2010.2008 (2011).
78. Vandenberghe, R. et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329, doi:10.1002/ana.22068 (2010).
79. Bourgeat, P. et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging 36(Suppl 1), S159-166, doi:10.1016/j. neurobiolaging.2014.04.033 (2015).
80. Villemagne, V. et al. En Attendant Centiloid. Advances in Research 2, 723-729 (2014).
81. Bourgeat, P. et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121-127, doi:10.1212/WNL.0b013e3181c918b5 (2010).
82. Dore, V. et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70, 903-911, doi:10.1001/jamaneurol.2013.1062 (2013).
83. Box, G. E. P. , Cox, D. R. An Analysis of Transformations. J Roy Stat Soc B 26, 211-252 (1964).